Stifel Nicolaus Boosts Danaher (NYSE:DHR) Price Target to $250.00

Danaher (NYSE:DHR) had its price objective lifted by Stifel Nicolaus from $235.00 to $250.00 in a report released on Wednesday morning, Benzinga reports. They currently have a hold rating on the conglomerate’s stock.

Other analysts also recently issued research reports about the stock. Citigroup upped their price target on shares of Danaher from $280.00 to $290.00 and gave the company a buy rating in a research report on Wednesday, April 24th. TD Cowen upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company a buy rating in a research report on Wednesday. HSBC upgraded shares of Danaher from a hold rating to a buy rating and upped their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Jefferies Financial Group assumed coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a buy rating and a $295.00 price target for the company. Finally, Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the company an outperform rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $276.88.

Danaher Stock Up 1.4 %

Shares of NYSE:DHR opened at $273.91 on Wednesday. The company has a market capitalization of $197.82 billion, a PE ratio of 46.43, a P/E/G ratio of 4.18 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.51 and a debt-to-equity ratio of 0.33. Danaher has a twelve month low of $182.09 and a twelve month high of $277.72. The firm has a 50 day simple moving average of $255.16 and a 200-day simple moving average of $249.22.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the firm earned $2.05 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. On average, equities analysts predict that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The disclosure for this sale can be found here. Insiders have sold a total of 84,775 shares of company stock valued at $21,802,690 in the last ninety days. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

A number of large investors have recently added to or reduced their stakes in the business. Cary Street Partners Investment Advisory LLC lifted its holdings in Danaher by 20.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares in the last quarter. First Citizens Bank & Trust Co. lifted its holdings in Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after purchasing an additional 149 shares in the last quarter. Cercano Management LLC lifted its holdings in Danaher by 11.4% in the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares in the last quarter. Finally, Donaldson Capital Management LLC lifted its holdings in Danaher by 5.8% in the 1st quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock valued at $367,000 after purchasing an additional 80 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.